Pasithea Therapeutics (KTTA) Competitors $0.74 -0.01 (-1.44%) Closing price 07/3/2025 03:35 PM EasternExtended Trading$0.74 0.00 (-0.14%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. GBIO, FGEN, FNCH, DARE, SLGL, MIRA, NAII, BCTX, RLMD, and DRRXShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Generation Bio (GBIO), FibroGen (FGEN), Finch Therapeutics Group (FNCH), Dare Bioscience (DARE), Sol-Gel Technologies (SLGL), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Relmada Therapeutics (RLMD), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors Generation Bio FibroGen Finch Therapeutics Group Dare Bioscience Sol-Gel Technologies MIRA Pharmaceuticals Natural Alternatives International Briacell Therap Relmada Therapeutics DURECT Pasithea Therapeutics (NASDAQ:KTTA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings. Do institutionals & insiders believe in KTTA or GBIO? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 16.3% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 21.8% of Generation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is KTTA or GBIO more profitable? Pasithea Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -292.92%. Generation Bio's return on equity of -75.84% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -88.14% -81.21% Generation Bio -292.92%-75.84%-30.40% Do analysts recommend KTTA or GBIO? Generation Bio has a consensus target price of $7.33, indicating a potential upside of 2,007.28%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Generation Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor KTTA or GBIO? In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Generation Bio'saverage media sentiment score. Company Overall Sentiment Pasithea Therapeutics Neutral Generation Bio Neutral Which has more risk and volatility, KTTA or GBIO? Pasithea Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Which has better earnings & valuation, KTTA or GBIO? Pasithea Therapeutics has higher earnings, but lower revenue than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.07Generation Bio$19.89M1.17-$131.67M-$1.08-0.32 SummaryGeneration Bio beats Pasithea Therapeutics on 10 of the 13 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.45M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.0721.7127.6420.25Price / SalesN/A281.12416.59118.23Price / CashN/A42.7336.8958.07Price / Book0.077.518.035.67Net Income-$13.90M-$55.14M$3.18B$249.21M7 Day Performance-2.90%4.61%2.92%3.28%1 Month Performance-16.25%4.72%3.72%5.55%1 Year Performance-85.46%5.92%35.14%21.08% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.0139 of 5 stars$0.74-1.4%N/A-85.8%$5.45MN/A-0.073Gap DownGBIOGeneration Bio2.9712 of 5 stars$0.320.0%$7.33+2,191.7%-85.7%$21.46M$19.89M-0.30150High Trading VolumeFGENFibroGen4.7157 of 5 stars$5.27-0.6%$250.00+4,643.8%-67.1%$21.42M$29.62M-2.11570Positive NewsInsider TradeGap UpFNCHFinch Therapeutics Group1.0849 of 5 stars$13.20flatN/A+921.5%$21.20M$110K-1.50190News CoverageDAREDare Bioscience1.6139 of 5 stars$2.37-0.8%$12.00+406.3%-22.3%$21.15M$10K-13.9430News CoverageSLGLSol-Gel Technologies2.6439 of 5 stars$7.40-0.1%$40.00+440.9%-17.9%$20.61M$11.54M-1.5750MIRAMIRA Pharmaceuticals2.9558 of 5 stars$1.21flat$14.00+1,057.0%+104.3%$20.47MN/A-2.372NAIINatural Alternatives International1.0408 of 5 stars$3.26-0.6%N/A-42.3%$20.27M$113.80M-2.35290Positive NewsBCTXBriacell Therap2.5369 of 5 stars$2.86-2.7%$32.00+1,018.9%-80.6%$19.92MN/A-0.348RLMDRelmada Therapeutics4.6217 of 5 stars$0.62+2.6%$5.00+711.6%-79.2%$19.92MN/A-0.2510Gap UpDRRXDURECT0.5473 of 5 stars$0.64+0.8%N/A-47.9%$19.72M$2.03M-4.2780Gap Down Related Companies and Tools Related Companies Generation Bio Alternatives FibroGen Alternatives Finch Therapeutics Group Alternatives Dare Bioscience Alternatives Sol-Gel Technologies Alternatives MIRA Pharmaceuticals Alternatives Natural Alternatives International Alternatives Briacell Therap Alternatives Relmada Therapeutics Alternatives DURECT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTA Stock Alerts